New Cardiovascular From Apeloa Approved For Phase I Trial
This article was originally published in PharmAsia News
Executive Summary
Zhejiang Apeloa Medical Technology has announced that an IND application for its drug salfaprodil has been approved, to allow the start of a Phase I clinical trial. The novel cardiovascular drug is being developed for the treatment of strokes.